Mode
Text Size
Log in / Sign up
Phase 3 N=105 Randomized Supportive Care

Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.

Nephrolithiasis

Enrolled (actual)
105
Serious AEs
11.4%
Results posted
Dec 2023
Primary outcome: Primary: Satisfaction With Pain Relief — 8.70; 8.85 score on a scale — p=0.70

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Ketorolac Oral Tablet [Toradol] (Drug); Acetaminophen (Drug); Oxycodone Acetaminophen (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Montefiore Medical Center
Primary completion
Mar 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Satisfaction With Pain Relief
8.70; 8.85 0.70
PRIMARY
Current Pain Intensity Level
1.14; 1.37 0.58
PRIMARY
Peak Pain Intensity Level
5.61; 7.52 0.006 sig
PRIMARY
Average Pain Intensity Level
3.34; 4.50 0.04 sig
PRIMARY
Perception of an Acceptable Pain Intensity Level
2.73; 3.28 0.33
SECONDARY
Unused Medications - Proportion of Prescribed Pills Unused at 1 Week Post-Surgery
0.63; 0.58 0.47
SECONDARY
Rates of Constipation
11; 17

Summary

There are two options for postoperative pain management: opioid and non-opioid analgesia. Pain outcomes will be compared in patients undergoing ureteroscopy and percutaneous nephrolithotomy by randomly administering opioid and non-opioid analgesia.

Eligibility Criteria

Inclusion Criteria

  • Men and Women age>18 years old
  • Presence of renal or ureteral stones suitable for ureteroscopy or percutaneous nephrolithotomy.
  • Uncomplicated ureteroscopy or percutaneous nephrolithotomy

Exclusion Criteria

  • Pregnant/Breastfeeding/Possibly Pregnant Patients
  • Pediatric Patients
  • Sensitive or Allergic to Opioids, Ketorolac, or Acetaminophen
  • Significant Renal Disease
  • Peptic Ulcer Disease
  • Chronic Pain and recovering opiate use
  • Inability to complete questionnaires
  • Non-mobile patients
  • Patients on methadone
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03584373). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search